Results 11 to 20 of about 42,088 (274)

The PCSK9 decade [PDF]

Journal of Lipid Research, 2012
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL receptor.
Gilles Lambert, Barbara Sjouke, Benjamin Choque, John J.P. Kastelein, G. Kees Hovingh   +4 more
doaj   +4 more sources

Naturally Occurring PCSK9 Inhibitors [PDF]

Nutrients, 2020
Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotein (LDL) cholesterol levels.
Maria Pia Adorni, Francesca Zimetti, Maria Giovanna Lupo, Massimiliano Ruscica, Nicola Ferri   +4 more
openalex   +7 more sources

Enzyme-Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors. [PDF]

Chembiochem
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important therapeutic target for lowering cholesterol. Here, we report the assembly of a bifunctional molecule combining a PCSK9‐binding peptide with an asialoglycoprotein receptor (ASGPR) ligand.
Zhang Y, Wang L, Corcilius L, Reji AK, Payne RJ, Hong B, Durek T, Wang CK, Craik DJ.   +8 more
europepmc   +2 more sources

PCSK9 Inhibitors [PDF]

Cell, 2016
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Pradeep, Natarajan, Sekar, Kathiresan
openaire   +3 more sources

PCSK9 antagonists and inflammation [PDF]

Atherosclerosis, 2018
Corsini, Alberto, Ferri, Nicola, Ruscica, Massimiliano, Sirtori, Cesare R.   +3 more
core   +5 more sources

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion

Hepatology, EarlyView., 2022
The role of SMLR1 in lipid metabolism (high fat + cholesterol diet in mice) Abstract Background and Aims The assembly and secretion of VLDL from the liver, a pathway that affects hepatic and plasma lipids, remains incompletely understood. We set out to identify players in the VLDL biogenesis pathway by identifying genes that are co‐expressed with the ...
Willemien van Zwol, Antoine Rimbert, Justina C. Wolters, Marieke Smit, Vincent W. Bloks, Niels J. Kloosterhuis, Nicolette C. A. Huijkman, Mirjam H. Koster, Umesh Tharehalli, Simon M. de Neck, Colin Bournez, Marceline M. Fuh, Jeroen Kuipers, Sujith Rajan, Alain de Bruin, Henry N. Ginsberg, Gerard J. P. van Westen, M. Mahmood Hussain, Ludger Scheja, Joerg Heeren, Philip Zimmerman, Bart van de Sluis, Jan Albert Kuivenhoven   +22 more
wiley   +1 more source

New approaches in detection and treatment of familial hypercholesterolemia [PDF]

, 2015
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that clinically leads to increased low density lipoprotein-cholesterol (LDL-C) levels. As a consequence, FH patients are at high risk for cardiovascular disease (CVD). Mutations
Hartgers, ML, Hovingh, GK, Ray, KK
core   +11 more sources

PCSK9 inhibitors

Swiss Medical Weekly, 2015
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces LDL receptor recycling, leading to a decrease of low-density lipoprotein cholesterol (LDL-C) receptors on the surface of hepatocytes and a subsequent increase of circulating LDL-C levels.
Gencer, B, Lambert, Gilles, Mach, François   +2 more
openaire   +7 more sources